Table 1 Baseline characteristics
Parameters | Patients (N = 99) |
|---|---|
Age (years) | 57.98 ± 10.33 |
Gender (Male/Female) | 89/10 |
Hepatitis history | |
No hepatitis history (n/%) | 3 (3.1) |
HBV (n/%) | 94 (94.9) |
HCV (n/%) | 2 (2.1) |
Drink (n/%) | 43 (43.4) |
Cirrhosis (n/%) | 55 (55.6) |
Tumor distributiona (%) | 20.0 (5.0–30.0) |
Number of nodules | |
1 (n/%) | 30 (30.1) |
> 1 (n/%) | 69 (69.9) |
< =3 (n/%) | 54 (54.5) |
> 3 (n/%) | 45 (45.5) |
Largest nodule size (cm) | 4.3 (2.1–8.3) |
Portal vein invasion (n/%) | 29 (29.3) |
Main portal vein invasion (n/%) | 8 (8.1) |
First branch invasion (n/%) | 8 (8.1) |
Second branch invasion (n/%) | 13 (13.1) |
Hepatic vein invasion (n/%) | 17 (17.2) |
ECOG performance status | |
0 (n/%) | 70 (70.7) |
1 (n/%) | 29 (29.3) |
Child-pugh Stage | |
A (n/%) | 91 (91.2) |
B (n/%) | 8 (8.1) |
BCLC Stage | |
A (n/%) | 24 (24.2) |
B (n/%) | 35 (35.4) |
C (n/%) | 40 (40.4) |
Laboratory Indexes | |
WBC abnormal (n/%) | 31 (31.3) |
RBC abnormal (n/%) | 16 (16.2) |
ANC abnormal (n/%) | 26 (26.3) |
HB abnormal (n/%) | 28 (28.3) |
80~ 100 g/L | 5 (5.1) |
> 100 g/L | 23 (23.2) |
PLT abnormal (n/%) | 28 (28.3) |
50~ 70 × 109/L | 19 (19.2) |
> 70 × 109/L | 9 (9.1) |
ALB abnormal (n/%) | 10 (10.1) |
TP abnormal (n/%) | 20 (20.2) |
TBIL abnormal (n/%) | 17 (17.2) |
21~ 34 μmol/L | 13 (13.1) |
34~ 51 μmol/L | 4 (4.0) |
TBA abnormal (n/%) | 29 (29.3) |
ALT abnormal (n/%) | 22 (22.2) |
AST abnormal (n/%) | 31 (31.3) |
1~ 2ULN | 25 (25.2) |
2~3ULN | 6 (6.1) |
ALP abnormal (n/%) | 19 (19.2) |
BCr abnormal (n/%) | 10 (10.1) |
BUN abnormal (n/%) | 9 (9.1) |
AFP abnormal (n/%) | 55 (55.6) |
20.0~ 400 ng/ml | 21 (21.2) |
> 400 ng/ml | 34 (34.3) |
CEA abnormal (n/%) | 12 (12.1) |
CA199 abnormal (n/%) | 19 (19.2) |
Previous treatment | |
cTACE (n/%) | 39 (39.4) |
cTACE times | 1 (1~ 2) |
Surgery (n/%) | 66 (66.7) |
Systematic chemotherapy (n/%) | 5 (5.1) |
Radiofrequency ablation (n/%) | 17 (17.2) |
Targeted therapy (n/%) | 1 (1.0) |
Chemoembolization reagents | |
Adriamycin (n/%) | 4 (4.1) |
Epirubicin (n/%) | 95 (95.9) |